Literature DB >> 17922731

Infective endocarditis in a hemodialysis patient: a dreaded complication.

Claudia Schubert1, Mohammed R Moosa.   

Abstract

Infection is the most common cause of death in hemodialysis patients, after cardiovascular disease. Dialysis access infections, with secondary septicemia, contribute significantly to patient mortality. The most common source is temporary catheterization. Bacteremia occurs commonly in patients receiving hemodialysis, with infective endocarditis being a relatively uncommon, but potentially lethal complication. Valvular calcification is the most significant risk factor. The diagnosis of infective endocarditis is made clinically and confirmed with the echocardiographic modified Duke's criteria. The most common pathogen is Staphylococcus aureus and the mitral valve is the most common site. Staphylococcus aureus infective endocarditis is commonly associated with embolic phenomenon. A high index of suspicion is critical in the early recognition and management of infective endocarditis. However, prevention of bacteremia is undoubtedly the best strategy with the early placement of arteriovenous fistulae. In the case of temporary catheterization, the use of topical mupirocin or polysporin and gentamicin and/or citrate locking is beneficial. Although catheter salvage has not been studied in randomized trials, catheter removal remains standard therapy during bacteremia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922731     DOI: 10.1111/j.1542-4758.2007.00204.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  2 in total

1.  Triboelectric charging of polytetrafluoroethylene antithrombotic catheters.

Authors:  Minoru Ogino; Kiyoshi Naemura; Satoshi Sasaki; Junko Minami; Takashi Kano; Nana Ito; Ryosuke Kasai; Fuminori Kamijyo; Naoki Kusumoto; Kazuya Akimoto; Kohei Tanaka; Kazuhiko Shinohara; Kenji Yokoyama
Journal:  J Artif Organs       Date:  2019-08-02       Impact factor: 1.731

2.  Membrane damage elicits an immunomodulatory program in Staphylococcus aureus.

Authors:  Ahmed S Attia; Meredith A Benson; Devin L Stauff; Victor J Torres; Eric P Skaar
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.